Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12621000484842
Ethics application status
Approved
Date submitted
9/02/2021
Date registered
26/04/2021
Date last updated
26/04/2021
Date data sharing statement initially provided
26/04/2021
Type of registration
Retrospectively registered

Titles & IDs
Public title
Targeted Screening for Congenital Cytomegalovirus-related Hearing loss in infants in Western Australia
Scientific title
Targeted Screening for Congenital Cytomegalovirus-related Hearing loss in infants up to 14 days old in Western Australia
Secondary ID [1] 303398 0
Funding body: Award reference: 2019_CG_Kuthubutheen
Universal Trial Number (UTN)
U1111-1264-8031
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Congenital CMV-related Hearing Loss 320684 0
Condition category
Condition code
Ear 318530 318530 0 0
Deafness
Infection 318840 318840 0 0
Other infectious diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Targeted testing of infants for congenital cytomegalovirus (cCMV).
Infants are targeted using the newborn hearing screen result.
Infants who fail ('refer') on newborn hearing screening are at increased risk of cCMV and (their parents/guardians) will be contacted to offer enrolment in the study - and testing for cCMV.
Currently testing is not routinely offered at this time point.
All infants in the state (meeting eligibility criteria) will be offered enrolment.
cCMV testing (saliva and urine) protocols in the study are the same as those used by the pathology centre and each request form is attached to a 'standard operating procedure' (SOP) instruction sheet approved by this centre.
The difference in the study is the testing time point, the methods of sampling and testing are standard.
Parents/guardians of the infant attend a community or hospital pathology centre (at the most convenient location for the family) which has been supplied with the request form and SOP. The pathology centre staff take a buccal swab from the infant (1 minute to complete) and the sample is processed in the standard manner. Study doctor/nurse inform the parents of the result. If this is negative the infant is discharged from the study. If it is positive, the infant again attends a pathology centre for confirmation of this via urine testing (nappy with cotton wool or specimen jar) which a gold standard testing protocol (if wet nappy, can taken within 1 minute, if not await wet nappy - usually less than 1 hour).
Study staff inform the family of the result, which if negative results in discharge from the study, if positive the usual care pathway (Audiology testing, ENT, Infectious diseases, Ophthalmology) is activated and expedited.
There are no further requirements from the infant and their family besides the saliva and urine testing, apart from access to the infants medical records which are reviewed for the duration of the (2 year) study to assess their clinical outcomes, in the cases of cCMV positive infants only.

The study staff assess testing attendance as every result is followed up - indicating willingness to participate. Additional investigative and treatment decision-making for cCMV positive infants is observed only.
Intervention code [1] 319704 0
Early detection / Screening
Comparator / control treatment
No control
Control group
Uncontrolled

Outcomes
Primary outcome [1] 326486 0
To assess whether targeted congenital cytomegalovirus testing is able to be completed by day 21 of life in Infants at high-risk of the virus across Western Australia

Used to assess this:
The proportion of infants unable to be recruited due to delayed NBHS testing/delayed communication of these results/unable to contact the parents or guardians by day 14 of life/infants who do not attend testing centres despite being enrolled

The electronic hospital results platform is used to determine attendance
Timepoint [1] 326486 0
Reported cCMV result by day 21 of life

Secondary outcome [1] 391655 0
To determine the incidence of congenital CMV (cCMV) infection in those infants who fail their newborn hearing screen in WA

The proportion of enrolled infants with a positive cCMV saliva and urine sample as a proportion of all infants tested is the measure of incidence
Timepoint [1] 391655 0
Cumulative testing data will be assessed at 6 months, 1 year and at the conclusion of the 2 year study
Secondary outcome [2] 391661 0
The proportion of participants not tested by day 21 of life as assessed via audit of patient electronic results platform
Timepoint [2] 391661 0
Cumulative testing data will be assessed at 6 months, 1 year and at the conclusion of the 2 year study
Secondary outcome [3] 391663 0
To determine the proportion of early diagnoses that result in time-critical treatment being administered as assessed via audit of the study database

Timepoint [3] 391663 0
Cumulative testing data will be assessed at 6 months, 1 year and at the conclusion of the 2 year study
Secondary outcome [4] 391667 0
Access has been approved by the hospital ethics committee and is explicitly stated during consent, to access the participants' medical records to determine the clinical progression of study participants during the study: including patterns of hearing loss, speech and language development and the meeting of other developmental milestones
Timepoint [4] 391667 0
Cumulative testing data will be assessed at 6 months, 1 year and at the conclusion of the 2 year study

Eligibility
Key inclusion criteria
During the 2 year study
1. all infants born in Western Australia undergoing newborn hearing screening which results in a 'refer' (fail) result in one or both ears
2. Are age less than day 11 for rural/remote infants and day 14 for infants in metropolitan area on the day the 'refer' result is received by the study team
3. Has a legally acceptable representative able to provide informed consent on behalf of the infant
Minimum age
No limit
Maximum age
14 Days
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Newborn hearing screen ‘refer’ result but infant aged over 11 days of age (rural/remote participants) and 14 days of age (metropolitan participant)
2. Medically unwell – although not specifically excluded from the study some Infants may be too unwell to reasonably take part. In consultation with the treating team, the research team would consider the appropriateness of approaching the guardians.
3. Lack of a legally acceptable representative able to provide informed consent on behalf of the infant.

Study design
Purpose of the study
Diagnosis
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation is not concealed
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
The number of eligible participants based on the WA annual birth rate and 2% ‘refer’ rate would equate 700 annual NBHS ‘refers’. Assuming an 80% enrolment rate we estimate that 560 referred babies per year will proceed to be swabbed. Assuming also, a conservative 2% rate of hearing loss attributable to cCMV in those who are swabbed, we expect to identify 11 cCMV patients out of approximately 560 participating referrals per year. Over the 2 year study period we would therefore expect to be able to estimate the incidence rate of congenital CMV infection in those who fail their NBHS with a margin of error of 1.7%, where the margin of error here is half of the 95% confidence interval width. The margin of error will be approximately 2% if only 600 swabs are obtained, say, for example, if recruitment was slower than expected or stopped after about 18 months. A Biostatistician has been consulted in relation to the power of the study.

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
2/11/2020
Date of last participant enrolment
Anticipated
7/11/2022
Actual
Date of last data collection
Anticipated
7/12/2022
Actual
Sample size
Target
140
Accrual to date
23
Final
Recruitment in Australia
Recruitment state(s)
WA
Recruitment hospital [1] 18664 0
Perth Children's Hospital - Nedlands

Funding & Sponsors
Funding source category [1] 307815 0
Charities/Societies/Foundations
Name [1] 307815 0
the Garnett-Passe Foundation
Country [1] 307815 0
Australia
Primary sponsor type
Individual
Name
Dr Jafri Kuthubutheen
Address
Perth Childrens Hospital, 15 Hospital Avenue Nedlands, Western Australia, 6009
Country
Australia
Secondary sponsor category [1] 308521 0
Hospital
Name [1] 308521 0
Perth Childrens Hospital
Address [1] 308521 0
Perth Childrens Hospital, 15 Hospital Avenue Nedlands, Western Australia 6009
Country [1] 308521 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 307821 0
Child and Adolescent Health Service: Human research Ethics Committee
Ethics committee address [1] 307821 0
Perth Children's Hospital
Level 5, Office 5E
15 Hospital Avenue
Nedlands, WA, 6009
Ethics committee country [1] 307821 0
Australia
Date submitted for ethics approval [1] 307821 0
Approval date [1] 307821 0
13/10/2020
Ethics approval number [1] 307821 0
RGS3073

Summary
Brief summary
Aim(s):
This project aims to examine the feasibility of establishing a state-wide screening program in WA to detect congenital CMV-related hearing loss in high-risk infants. The project does not aim to determine if early treatments are effective, this is outside of the scope of the study.

Primary Objectives:
1. To determine the incidence of congenital CMV infection in those infants who fail their newborn hearing screen in WA

2. To monitor the clinical progression of these patients/participants over time and their patterns of hearing loss to be able to better understand the disease in WA

Secondary objectives:

1. a) To identify and address potential barriers to early detection of cCMV (less than 21 days) in order to facilitate feasible (cost-effective, minimally invasive) diagnosis via a saliva swab
b) To determine whether early diagnosis has the potential to make time-critical treatment possible (within 30 days).

2. If targeted testing is found to be feasible - to create and implement a protocol which forms a clinical pathway for targeted testing of infants at high-risk of cCMV in WA.

Hypothesis:
We hypothesise that timely targeted cCMV screening is both important and feasible to implement into WA Newborn Hearing Screening Guidelines.
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 108618 0
Dr Jafri Kuthubutheen
Address 108618 0
Ear, nose and Throat Department
Perth Children's Hospital
15 Hospital Ave, Nedlands WA 6009
Country 108618 0
Australia
Phone 108618 0
+61401679302
Fax 108618 0
Email 108618 0
[email protected]
Contact person for public queries
Name 108619 0
Allison Reid
Address 108619 0
Ear, nose and Throat Department
Perth Children's Hospital
15 Hospital Ave, Nedlands WA 6009
Country 108619 0
Australia
Phone 108619 0
+61 08 6456 2222
Fax 108619 0
Email 108619 0
[email protected]
Contact person for scientific queries
Name 108620 0
Allison Reid
Address 108620 0
Ear, nose and Throat Department
Perth Children's Hospital
15 Hospital Ave, Nedlands WA 6009
Country 108620 0
Australia
Phone 108620 0
+61 08 6456 2222
Fax 108620 0
Email 108620 0
[email protected]

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment
Aggregated data will be available.
Individual participant data will not due to relatively limited numbers of positives expected and that these patients may be identifiable (even to themselves) because of this.


What supporting documents are/will be available?

Doc. No.TypeCitationLinkEmailOther DetailsAttachment
10523Study protocol  [email protected]
10524Ethical approval  [email protected] 381390-(Uploaded-09-02-2021-15-08-34)-Study-related document.pdf
10525Informed consent form  [email protected]



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
EmbaseCongenital cytomegalovirus: the case for targeted infant screening in Australia.2022https://dx.doi.org/10.5694/mja2.51406
N.B. These documents automatically identified may not have been verified by the study sponsor.